Mountain Crest Acquisition Corp. V: directors' dealings · United States · SEC (Form 4)

About Mountain Crest Acquisition Corp. V

Mountain Crest Acquisition Corp. V is a U.S.-listed special purpose acquisition company (SPAC) incorporated in Delaware and headquartered in New York, United States. It completed its IPO on the Nasdaq in November 2021 under the ticker MCAG, while the rights traded separately under MCAGU. In the current SEC reporting framework, MCAGU is visible primarily through insider-ownership disclosures such as Form 4 filings, which is consistent with a blank-check vehicle whose market story is driven by merger execution rather than operating earnings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1859035/000182912626002303/mountaincrest5_10k.htm)) From a business-model perspective, Mountain Crest V does not function like a traditional industrial or consumer company. Its sole purpose is to identify, negotiate, and consummate a business combination with one or more operating businesses through a merger, share exchange, asset acquisition, stock purchase, recapitalization, or similar transaction. SEC filings state that, since the IPO, the company’s only substantive activity has been identifying and evaluating suitable acquisition candidates. That means the equity case is inherently event-driven: upside depends on closing a transaction, while downside risk remains tied to delay, dilution, financing needs, and the possibility that no deal is completed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1859035/000182912626002303/mountaincrest5_10k.htm)) The company’s history is closely linked to the broader Mountain Crest SPAC platform. A company filing in August 2024 describes Mountain Crest V as the fifth vehicle in the Mountain Crest family of SPACs and notes that management had previously completed four prior SPAC business combinations. On August 29, 2024, Mountain Crest V announced a definitive business combination agreement with CUBEBIO Co., Ltd., a Korean company developing early cancer-detection technology based on urine analysis. The contemplated post-transaction company is expected to be listed on the Nasdaq, underscoring the cross-border nature of the deal. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1859035/000182912624005987/mountaincrest5_ex99-1.htm?utm_source=openai)) In terms of competitive positioning, Mountain Crest V operates in a crowded SPAC market where sponsor credibility, deal sourcing, valuation discipline, and the ability to navigate SEC and shareholder approvals are the main differentiators. Its geographic footprint is largely U.S.-based, with New York as the operating center, but its target universe is international, as shown by the CUBEBIO transaction spanning the United States, South Korea, and Cayman Islands holding-company structures. Recent corporate developments include an extension of the business-combination deadline to November 16, 2026, a later SEC filing indicating the securities were moved from Nasdaq to OTC Pink after delisting, and ongoing insider transactions reported through Form 4. Those items suggest a company still focused on completing a transaction rather than generating conventional operating revenue. ([investing.com](https://www.investing.com/news/sec-filings/mountain-crest-acquisition-corp-v-extends-business-combination-deadline-to-november-2026-93CH-4344198?utm_source=openai))